CEL-SCI Corp (CVM) - Total Liabilities
Based on the latest financial reports, CEL-SCI Corp (CVM) has total liabilities worth $11.76 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore CVM net assets growth trend to track the company's year-over-year net asset growth rate.
CEL-SCI Corp - Total Liabilities Trend (1986–2025)
This chart illustrates how CEL-SCI Corp's total liabilities have evolved over time, based on quarterly financial data. See CVM free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
CEL-SCI Corp Competitors by Total Liabilities
The table below lists competitors of CEL-SCI Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Field Solutions Holdings Ltd
AU:FSG
|
Australia | AU$48.22 Million |
|
Ryukil C&S Ltd
KQ:191410
|
Korea | ₩33.07 Billion |
|
Kingfish Company Nv
OL:KING
|
Norway | Nkr122.14 Million |
|
Lease IT Public Company Limited
BK:LIT
|
Thailand | ฿536.69 Million |
|
Bodhi Tree Multimedia Limited
NSE:BTML
|
India | Rs817.62 Million |
|
CBL International Limited Ordinary Shares
NASDAQ:BANL
|
USA | $39.56 Million |
|
Innodep Inc.
KQ:303530
|
Korea | ₩38.83 Billion |
|
Interwood-Xylemporia A.T.E.N.E.
AT:XYLEK
|
Greece | €36.40 Million |
Liability Composition Analysis (1986–2025)
This chart breaks down CEL-SCI Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CEL-SCI Corp (CVM) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 1.25 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CEL-SCI Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CEL-SCI Corp (1986–2025)
The table below shows the annual total liabilities of CEL-SCI Corp from 1986 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | $12.20 Million | -13.64% |
| 2024-09-30 | $14.12 Million | -18.42% |
| 2023-09-30 | $17.31 Million | -5.70% |
| 2022-09-30 | $18.36 Million | -5.04% |
| 2021-09-30 | $19.34 Million | -7.08% |
| 2020-09-30 | $20.81 Million | -7.47% |
| 2019-09-30 | $22.49 Million | -23.99% |
| 2018-09-30 | $29.59 Million | +12.66% |
| 2017-09-30 | $26.26 Million | +109.18% |
| 2016-09-30 | $12.55 Million | -39.29% |
| 2015-09-30 | $20.68 Million | +135.32% |
| 2014-09-30 | $8.79 Million | +112.33% |
| 2013-09-30 | $4.14 Million | -54.22% |
| 2012-09-30 | $9.04 Million | -5.31% |
| 2011-09-30 | $9.55 Million | -4.06% |
| 2010-09-30 | $9.95 Million | -73.24% |
| 2009-09-30 | $37.19 Million | +866.49% |
| 2008-09-30 | $3.85 Million | -36.52% |
| 2007-09-30 | $6.06 Million | -42.74% |
| 2006-09-30 | $10.58 Million | +971.99% |
| 2005-09-30 | $987.31K | +357.13% |
| 2004-09-30 | $215.98K | -87.22% |
| 2003-09-30 | $1.69 Million | -37.61% |
| 2002-09-30 | $2.71 Million | +433.57% |
| 2001-09-30 | $507.73K | -40.09% |
| 2000-09-30 | $847.42K | +69.48% |
| 1999-09-30 | $500.00K | +25.00% |
| 1998-09-30 | $400.00K | -20.00% |
| 1997-09-30 | $500.00K | +66.67% |
| 1996-09-30 | $300.00K | -81.25% |
| 1995-09-30 | $1.60 Million | +14.29% |
| 1994-09-30 | $1.40 Million | +100.00% |
| 1993-09-30 | $700.00K | +40.00% |
| 1992-09-30 | $500.00K | -28.57% |
| 1991-09-30 | $700.00K | +40.00% |
| 1990-09-30 | $500.00K | 0.00% |
| 1989-09-30 | $500.00K | -28.57% |
| 1988-09-30 | $700.00K | +133.33% |
| 1987-09-30 | $300.00K | -25.00% |
| 1986-09-30 | $400.00K | -- |
About CEL-SCI Corp
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation S… Read more